The startup is developing a patent-protected combination therapy for chronic rhinosinusitis that targets underlying inflammation and bacterial biofilm. This treatment aims to provide patients with a safe and effective alternative to current management options, offering lasting relief from sinus pain and improved quality of life.
Funding
Funding not disclosed
Founders
Product
Problem
Chronic rhinosinusitis (CRS) affects millions, causing persistent nasal inflammation, congestion, and pain. Current treatments, such as antibiotics and nasal sprays, often fail to provide adequate relief or address the underlying inflammation and bacterial biofilms. Existing therapies may also lead to side effects, antibiotic resistance, or require invasive procedures.
Solution
Diceros Therapeutics is developing Verasone™, a patent-protected, dual-action combination therapy for chronic rhinosinusitis (CRS). Verasone™ combines two existing therapies into a single treatment delivered via high-volume sinonasal irrigation, ensuring direct and effective drug delivery to the sinuses. This approach targets both inflammation and bacterial biofilms, offering improved clinical efficacy and reduced side effects compared to current treatment modalities. Verasone™ is currently undergoing clinical trials to validate its effectiveness in providing lasting relief from CRS symptoms.
Target Audience
The primary target audience includes individuals suffering from chronic rhinosinusitis (CRS), as well as physicians, ENTs, and healthcare providers seeking more effective and well-tolerated treatment options.
Features
- Proprietary combination of two existing therapies with evidence-based efficacy.
- Dual mechanism of action targeting both inflammation and bacterial biofilms.
- Administered via high-volume sinonasal irrigation for direct and effective drug delivery.
- Designed to improve clinical efficacy and reduce side effects compared to existing treatments.
- Currently undergoing clinical trials to validate safety and efficacy.